2021 American Transplant Congress
CEACAM1 Signaling is Essential to Elicit Tim-3 Inhibitory Regulation in Liver Transplantation
The Dumont-UCLA Transplantation Center, Los Angeles, CA
*Purpose: T cell immunoglobulin domain and mucin domain-3 (TIM-3) has been reported to induce T cell exhaustion. By alleviating hepatic ischemia-reperfusion injury, we have explored…2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…2021 American Transplant Congress
Tubastatin-a Mediated Protection from Liver Injury is Preserved in a Lymphocyte Deficient Model
1University of Pennsylvania, Philadelphia, PA, 2University of Illinois at Chicago, Chicago, IL
*Purpose: Liver Ischemia reperfusion injury (IRI) and Acetaminophen (APAP) toxicity are important causes of acute liver failure in the United States, that lack effective therapy.…2021 American Transplant Congress
Evaluation of High-versus Low-Dose Valganciclovir for Cytomegalovirus Prevention in Adult Liver Transplant Recipients: A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is the most common infection after solid organ transplantation and is associated with increased morbidity and mortality. CMV prophylaxis is widely considered…2021 American Transplant Congress
Blood Pressure Variability Immediately After Liver Transplant Predicts the Likelihood of Long-Term Cardiovascular Events
*Purpose: Cardiovascular disease is a leading cause of mortality in liver transplant recipients (LTRs). Adequate blood pressure (BP) control within one year after liver transplant…2021 American Transplant Congress
Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma
*Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…2021 American Transplant Congress
Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score
1Johns Hopkins Medical Institutions, Baltimore, MD, 2Temple University, Philadelphia, PA
*Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…2021 American Transplant Congress
Comparison of Outcomes of Living Donor Liver Transplantation for Biliary Atresia Patients with and without Kasai Portoenterostomy
*Purpose: We evaluated 10 year outcomes and the potential predictors of outcomes after living donor liver transplant (LT) for biliary atresia (BA) patients with and…2021 American Transplant Congress
Validation of a Novel Gene Expression Biomarker of Rejection Following Liver Transplantation
*Purpose: Non-invasive biomarkers distinguishing early signs of immune activation vs. quiescence could more objectively guide immunosuppression management after liver transplantation (LT). Our aim was to…2021 American Transplant Congress
Clinical Correlation of Frailty Measures and Evaluation of Complementary Molecular Frailty Biomarker Candidates in a Prospective National Cohort of Liver Transplant Candidates
*Purpose: Frailty is a clinical condition characterized by a loss of physiologic reserve and increased susceptibility to stressors. Molecular frailty biomarkers may reflect the dysregulation…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 180
- Next Page »